...The partners amended a 2005 deal under which Xenetic (formerly Lipoxen plc ) granted Baxter exclusive rights...

...I trial to evaluate 3 dose levels of PSA-Oxyntomodulin in 12 healthy volunteers. Xenetic (formerly Lipoxen plc...

...trial to evaluate 2,500 and 5,000 units of PulmoXen in 12 healthy volunteers. Xenetic (formerly Lipoxen plc...

...and PulmoXen outside of Russia under a November 2009 deal. Xenetic was formerly known as Lipoxen plc...

...in the third part. Pharmsynthez has exclusive rights to MyeloXen in Russia, while Xenetic (formerly Lipoxen plc...

...under the deal, including a preclinical 13 valent pneumococcal vaccine and StimuXen . Xenetic (formerly Lipoxen plc...

...Xenetic (formerly Lipoxen plc ) completed its acquisition of cancer company SymbioTec. SymbioTec shareholders received 80 million...

...Xenetic, formerly Lipoxen plc , had expected to complete the acquisition by Dec. 15. In July, Lipoxen...

...close of 9.25p on Aug. 3, the day before the offering was announced. Xenetic (formerly Lipoxen plc...

...will acquire cancer company SymbioTec in a stock deal valued at £8.8 million ($14.5 million). Lipoxen...
...acute myelogenous leukemia (AML). Lipoxen plans to change its name to Xenetic Biosciences plc . Lipoxen plc...